• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Directories » FDA Approved Drugs » Cometriq (cabozantinib)

AND
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Cometriq (cabozantinib)

  • Profile

Profile

Contact Information

Currently Enrolling Trials

    Show More

    General Information

    Cometriq (cabozantinib) is a pan-tyrosine kinase inhibitor. These receptor tyrosine kinases are involved in both normal cellular function and pathologic processes such as oncogenesis, metastasis, tumor angiogenesis, and maintenance of the tumor microenvironment.

    Cometriq is specifically approved for the treatment of progressive, metastatic medullary thyroid cancer.

    Cometriq is supplied as a capsule for oral administration. The recommended daily dose of Cometriq is 140 mg (one 80-mg and three 20-mg capsules). Cometriq should not be administered with food. Patients should not to eat for at least 2 hours before and at least 1 hour after taking Cometriq. Continue treatment until disease progression or unacceptable toxicity occurs.

    Clinical Results

    FDA Approval
    The FDA approval of Cometriq was based on an international, multi-center, randomized, double-blind, controlled trial in 330 subjects with metastatic medullary thyroid carcinoma (MTC). The subjects were required to have evidence of actively progressive disease within 14 months prior to study entry confirmed by an Independent Radiology Review Committee or the treating physician. Subjects were randomized to receive Cometriq 140 mg or placebo orally once daily, without food, until disease progression or until intolerable toxicity. Randomization was stratified by age (< 65 years vs. > 65 years) and prior use of a tyrosine kinase inhibitor. The main efficacy outcome measures were progression-free survival (PFS), objective response (OR), and response duration using modified RECIST criteria. A statistically significant prolongation in PFS was demonstrated among the Cometriq-treated arm compared to placebo (p <0.0001), with median PFS times of 11.2 months and 4.0 months in the Cometriq and placebo arms, respectively. Partial responses were observed only among subjects in the Cometriq arm (27% vs. 0; p<0.0001). The median duration of objective responses was 14.7 months for subjects treated with Cometriq. There was no statistically significant difference in overall survival between the treatment arms at the planned interim analysis.

    Side Effects

    Adverse events associated with the use of Cometriq may include, but are not limited to, the following:

    • diarrhea
    • stomatitis
    • palmar-plantar erythrodysesthesia syndrome
    • decreased weight
    • decreased appetite
    • nausea
    • fatigue
    • oral pain
    • hair color changes
    • dysgeusia
    • hypertension
    • abdominal pain
    • constipation

    Mechanism of Action

    Cometriq (cabozantinib) inhibits the tyrosine kinase activity of RET, MET, VEGFR-1, -2 and -3, KIT, TRKB, FLT-3, AXL, and TIE-2. These receptor tyrosine kinases are involved in both normal cellular function and pathologic processes such as oncogenesis, metastasis, tumor angiogenesis, and maintenance of the tumor microenvironment.

    Additional Information

    For additional information regarding Cometriq or metastatic medullary thyroid cancer, please visit the Cometriq web page.

    Approval Date: 2012-11-01
    Company Name: Exelixis
    Back to Listings

    Upcoming Events

    • 26Jan

      Reducing Complexity in Starting Clinical Trials – More Patients, Faster Startup

    • 27Jan

      Medical Device Clinical Trials in China: Latest Regulatory Developments

    • 11Feb

      Lab X.0: Addressing Quality and Compliance Challenges in Laboratory Operations in the COVID-19 All-Digital Era

    • 23Mar

      Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

    • 26Apr

      MAGI's Clinical Research vConference — Spring 2021

    Featured Products

    • Regenerative Medicine – Steps to Accelerate Development : PDF

      Regenerative Medicine: Steps to Accelerate Development

    • Clinical Trial Agreements — A Guide to Key Words and Phrases : PDF

      Clinical Trial Agreements: A Guide to Key Words and Phrases

    Featured Stories

    • Resources-360x240.png

      Trial Complexity, Endpoints Continue to Increase, Stretching Site Resources

    • FocusinRed-360x240.png

      Return to Focus on Risk Management Postpandemic Could Prove Challenging to Sites

    • VaccinewithNeedle-360x240.png

      2021 Vaccine Industry Will Continue to be Dominated by COVID-19 Trials, Experts Say

    • Dominate-360x240.png

      COVID-19, Oncology, CNS and Infectious Disease Trials Will Dominate in 2021, Survey Predicts

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell My Personal Information

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 617.948.5100 – Toll free 866.219.3440

    Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing